Clinical Trial Update: Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Nabiximols Oromucosal Spray for spasticity in people with multiple sclerosis was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Nabiximols Oromucosal Spray (nabiximols)

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: Spasticity With Multiple Sclerosis | Phase 3 | Status: TERMINATED | Results posted: 2024-02-05